Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis Results of a Randomized Controlled Trial

被引:71
作者
Bissonnette, Robert [1 ]
Tardif, Jean-Claude [2 ]
Harel, Francois [2 ]
Pressacco, Josephine [2 ]
Bolduc, Chantal [1 ]
Guertin, Marie-Claude [3 ]
机构
[1] Innovaderm Res Inc, Dept Dermatol, Montreal, PQ, Canada
[2] Univ Montreal, Montreal Heart Inst, Res Ctr, Montreal, PQ, Canada
[3] MHICC, Montreal, PQ H1T 1C8, Canada
关键词
aorta; atherosclerosis; carotid arteries; inflammation; inhibitors; C-REACTIVE PROTEIN; MYOCARDIAL-INFARCTION; PLAQUE INFLAMMATION; CORONARY-ARTERY; CARDIOVASCULAR EVENTS; RHEUMATOID-ARTHRITIS; RISK; THERAPY; DISEASE; ATHEROSCLEROSIS;
D O I
10.1161/CIRCIMAGING.112.975730
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Psoriasis is a chronic inflammatory disease associated with increased risks of myocardial infarction and stroke. Systemic treatments for moderate to severe psoriasis can reduce skin and joint inflammation; however, their effects on vascular inflammation are unknown. Methods and Results This randomized, controlled trial included 30 patients with moderate to severe psoriasis and a history, or multiple risk factors, of coronary atherosclerosis. Patients were randomized (2:1) to receive either adalimumab subcutaneously for 4 months or to control nonsystemic treatment (topical therapies or phototherapy). Vascular inflammation was measured in the carotid artery and ascending aorta at baseline and week 15, by F-18-fluorodeoxyglucose uptake on positron emission tomography. The change in target:background ratio in the vessel with highest baseline target:background ratio (primary end point) was significant at week 15 compared with baseline for patients randomized to adalimumab (-0.23 [95% CI, -0.39 to -0.08]; P=0.004) but not for the control group (-0.10 [95% CI, -0.32 to 0.12]; P=0.35). The difference between study arms for this primary end point did not reach statistical significance (-0.13 [95% CI, -0.01 to 0.14]; P=0.32). The change in target:background ratio at week 15 improved with adalimumab compared with controls both in the ascending aorta (-0.26 +/- 0.11, P=0.021) and in carotid arteries (-0.32 +/- 0.15, P=0.037) when analyzed separately (secondary end points). Changes in other positron emission tomography indices also improved significantly with adalimumab compared with controls in the ascending aorta and carotids. High-sensitivity C-reactive protein decreased by 51% at week 16 with adalimumab compared with 5% in controls (P=0 center dot 002). Conclusions The study did not meet its primary end point because the change in target:background ratio in patients randomized to adalimumab was not different from controls. Although adalimumab may reduce vascular inflammation in patients with moderate to severe psoriasis, this effect is not large enough to be demonstrated in a study with a small sample size. Clinical Trial Registration URL: . Unique identifier: NTC00940862.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 36 条
[1]   The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study [J].
Abuabara, K. ;
Lee, H. ;
Kimball, A. B. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (05) :1066-1073
[2]   Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study [J].
Ahlehoff, O. ;
Gislason, G. H. ;
Lindhardsen, J. ;
Olesen, J. B. ;
Charlot, M. ;
Skov, L. ;
Torp-Pedersen, C. ;
Hansen, P. R. .
JOURNAL OF INTERNAL MEDICINE, 2011, 270 (03) :237-244
[3]   C-Reactive Protein Is a Determinant of First-Ever Stroke: Prospective Nested Case-Referent Study [J].
Andersson, Jonas ;
Johansson, Lars ;
Ladenvall, Per ;
Wiklund, Per-Gunnar ;
Stegmayr, Birgitta ;
Jern, Christina ;
Boman, Kurt .
CEREBROVASCULAR DISEASES, 2009, 27 (06) :544-551
[4]   Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions [J].
Davidovici, Batya B. ;
Sattar, Naveed ;
Joerg, Prinz C. ;
Puig, Luis ;
Emery, Paul ;
Barker, Jonathan N. ;
van de Kerkhof, Peter ;
Stahle, Mona ;
Nestle, Frank O. ;
Girolomoni, Giampiero ;
Krueger, James G. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (07) :1785-1796
[5]   Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy -: Results from the British Society for Rheumatology Biologics Register [J].
Dixon, W. G. ;
Watson, K. D. ;
Lunt, M. ;
Silman, A. J. ;
Hyrich, K. L. ;
Symmons, D. P. M. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (09) :2905-2912
[6]   Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability [J].
Erbel, Christian ;
Dengler, Thomas J. ;
Wangler, Susanne ;
Lasitschka, Felix ;
Bea, Florian ;
Wambsganss, Nadine ;
Hakimi, Maani ;
Boeckler, Dittmar ;
Katus, Hugo A. ;
Gleissner, Christian A. .
BASIC RESEARCH IN CARDIOLOGY, 2011, 106 (01) :125-134
[7]   Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial [J].
Fayad, Zahi A. ;
Mani, Venkatesh ;
Woodward, Mark ;
Kallend, David ;
Abt, Markus ;
Burgess, Tracy ;
Fuster, Valentin ;
Ballantyne, Christie M. ;
Stein, Evan A. ;
Tardif, Jean-Claude ;
Rudd, James H. F. ;
Farkouh, Michael E. ;
Tawakol, Ahmed .
LANCET, 2011, 378 (9802) :1547-1559
[8]   SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].
FREDRIKSSON, T ;
PETTERSSON, U .
DERMATOLOGICA, 1978, 157 (04) :238-244
[9]   Risk of myocardial infarction in patients with psoriasis [J].
Gelfand, Joel M. ;
Neimann, Andrea L. ;
Shin, Daniel B. ;
Wang, Xingmei ;
Margolis, David J. ;
Troxel, Andrea B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (14) :1735-1741
[10]   The Risk of Stroke in Patients with Psoriasis [J].
Gelfand, Joel M. ;
Dommasch, Erica D. ;
Shin, Daniel B. ;
Azfar, Rahat S. ;
Kurd, Shanu K. ;
Wang, Xingmei ;
Troxel, Andrea B. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (10) :2411-2418